DX&Vx Completes Patent Application for New Oral Obesity Treatment Drug Candidate

Dx&Vx announced on the 26th that it has completed the patent application for its orally administered obesity treatment (GLP-1RA), a low-molecular GLP-1 receptor agonist developed in-house.

The company initially aimed to file two patent applications in the third quarter. By filing one of the candidate substances early on this day, it announced the acceleration of new drug development.

The core of Dx&Vx's patent application candidate substance lies in its structural originality compared to existing developers. It also overcomes the drawbacks of existing peptide-based GLP-1RA treatments, such as the inconvenience of injection administration and high production costs. It is characterized by being designed for oral administration. Additionally, by minimizing degradation in the gastrointestinal tract and increasing bioavailability, it can maximize therapeutic effects.

Starting with this patent application, Dx&Vx plans to promptly proceed with additional research and development such as animal testing and to actively prepare for entry into clinical trials. The company also plans to establish a foundation for global clinical trials and market entry through various partnerships with multiple global pharmaceutical companies.

CEO Kwon Kyu-chan stated, “The patent application, which was advanced ahead of the originally planned schedule, is an example demonstrating the company's outstanding research and development capabilities and rapid development speed, reflecting the company's strong commitment to new drug development.” He emphasized, “We will continue to produce results swiftly in clinical trials and commercialization stages, establishing a leading position in the global obesity treatment market, which is expected to grow to a market size of 100 trillion won by 2030.”

Currently, Dx&Vx is expanding its new drug pipeline targeting various indications. The patent application for this orally administered obesity treatment (GLP-1RA) candidate substance is seen as an important turning point in new drug development.

Meanwhile, 임종윤 (Im Jong-yoon), an inside director of Hanmi Pharmaceutical Group, is the largest shareholder of Dx&Vx. The company is intensively investing in recruiting global talent and research and development (R&D) capabilities for the development of anticancer and infectious disease vaccines as well as new drugs for obesity and metabolic diseases.

Recently, the company announced that it will strengthen cooperation with the Kori Group, utilizing the core technologies and global network established by the Kori Group to further advance clinical and business operations.